葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GSK 葛兰素史克

交易中 11-04 14:56:14 EST

51.08

+2.38

+4.88%

最高51.29	最低50.08	成交量383.20万
今开50.80	昨收48.70	日振幅2.47%
总市值1,033亿	流通市值990.85亿	总股本20.23亿
成交额1.95亿	换手率0.20%	流通股本19.40亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"葛兰素史克","latestPrice":51.075,"timestamp":1793822169771,"preClose":48.7,"halted":0,"volume":3832016,"delay":0,"changeRate":0.04876796714579055,"floatShares":1939999999,"shares":2022697682,"eps":2.832394,"marketStatus":"交易中","change":2.375,"latestTime":"11-04 14:56:14 EST","open":50.8,"high":51.285,"low":50.08,"amount":194635680.03168002,"amplitude":0.024743,"askPrice":51.08,"askSize":434,"bidPrice":51.07,"bidSize":429,"shortable":3,"etf":0,"ttmEps":2.832394,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1793826000000},"marketStatusCode":2,"adr":1,"adrRate":2,"listingDate":977893200000,"exchange":"NYSE","adjPreClose":48.7,"dividendRate":0.035109,"preHourTrading":{"tag":"盘前","latestPrice":50.83,"preClose":48.7,"latestTime":"09:29 EST","volume":113270,"amount":5708909.71646,"timestamp":1793802599081,"change":2.13,"changeRate":0.043737,"amplitude":0.047639},"postHourTrading":{"tag":"盘后","latestPrice":48.76,"preClose":48.7,"latestTime":"19:56 EST","volume":15117,"amount":736355.4388,"timestamp":1793753816664,"change":0.06,"changeRate":0.001232,"amplitude":0.019918},"volumeRatio":0.941896,"impliedVol":0.2769,"impliedVolPercentile":0.3068},"requestUrl":"/m/hq/s/GSK","defaultTab":"news","newsList":[{"id":"1177882516","title":"异动解读｜葛兰素史克盘中上涨4.3%，合作研究消息叠加财报后估值博弈","url":"https://stock-news.laohu8.com/highlight/detail?id=1177882516","media":"行情直击","labels":[],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177882516?lang=zh_cn&edition=full","pubTime":"2026-11-05 00:13","pubTimestamp":1793808787,"startTime":"0","endTime":"0","summary":"11月5日，葛兰素史克盘中上涨4.3%，报50.795美元/股，成交额1.27亿美元。消息面上，公司最新宣布将与Alamar Biosciences合作，利用Nulisa平台研究循环蛋白特征与疾病进展，强化早期研发工具布局。此外，公司此前三季度营收88.9亿英镑、调整后每股收益1.47美元，均高于预期，全年指引维持不变；尽管近日有机构下调评级和目标价，但主流目标价仍高于现价，市场对其管线价值与增长前景仍存重新定价空间。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"葛兰素史克盘中拉升，合作研究点燃估值重估","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157725874","title":"异动解读｜葛兰素史克盘前上涨4.09%，投行下调后估值分歧仍存","url":"https://stock-news.laohu8.com/highlight/detail?id=1157725874","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157725874?lang=zh_cn&edition=full","pubTime":"2026-11-04 20:50","pubTimestamp":1793796649,"startTime":"0","endTime":"0","summary":"11月4日，葛兰素史克盘前上涨4.09%，报50.69美元/股，成交额226.83万美元。近期消息面上，机构观点出现分化：Jefferies将该股评级下调至持有，目标价55.90美元；RBC将伦敦股目标价由19.75英镑下调至19.25英镑，但维持行业表现评级。尽管卖方态度趋于谨慎，当前目标价仍高于现价，市场对公司估值与后续增长预期仍有博弈。此前公司三季度营收88.9亿英镑，同比增长4%，全年指引维持不变，肿瘤、呼吸免疫炎症及HIV业务保持增长，但疫苗业务承压。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"葛兰素史克盘前上涨，机构估值分歧仍存","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680709158","title":"Alamar Biosciences称，将使用其Nulisa平台与葛兰素史克(GSK)合作，研究循环蛋白特征和疾病进展。","url":"https://stock-news.laohu8.com/highlight/detail?id=2680709158","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680709158?lang=zh_cn&edition=full","pubTime":"2026-11-04 08:08","pubTimestamp":1793750895,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["GSK.UK","GSKH","BK4585","BK4588","BK4007","LU1829250122.USD","GSK","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187042644","title":"异动解读｜葛兰素史克盘中上涨3.14%，投行下调评级后股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1187042644","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187042644?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:06","pubTimestamp":1793369163,"startTime":"0","endTime":"0","summary":"10月30日，葛兰素史克盘中上涨3.14%，报49.51美元/股，成交额2970.18万美元。消息面上，前一交易日公司接连遭遇投行偏谨慎表态，Jefferies将其评级下调至持有，目标价55.90美元；RBC则将伦敦股目标价由19.75英镑下调至19.25英镑，维持行业表现评级。此前公司三季度营收88.9亿英镑，同比增长4%，高于市场预期的88.3亿英镑，但核心每股收益0.546英镑，低于预期的0.589英镑。公司维持全年收入增长3%至5%、核心每股收益增长7%至9%的指引，股价在前期回落后出现反弹。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"投行下调评级后，葛兰素史克反弹上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174097936","title":"异动解读｜葛兰素史克盘中下跌6.72%，Q3核心每股收益同比下滑且低于市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1174097936","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174097936?lang=zh_cn&edition=full","pubTime":"2026-10-28 21:31","pubTimestamp":1793194305,"startTime":"0","endTime":"0","summary":"10月28日，葛兰素史克盘中下跌6.72%，报47.48美元/股，成交额6011.51万美元。消息面上，公司披露第三季度财报后股价走弱。季度核心每股收益为0.546英镑，低于上年同期的0.55英镑，也低于市场预期的0.589英镑；不过当季营收88.9亿英镑，同比增长4%，略高于市场预期的88.3亿英镑。公司同时维持全年收入增长3%至5%、核心每股收益增长7%至9%的指引，市场更关注盈利端承压信号。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"葛兰素史克股价下挫，Q3盈利不及预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678450628","title":"葛兰素史克（GSK）三季度非GAAP每股收益0.55英镑超预期 拟派发每股17便士季度股息","url":"https://stock-news.laohu8.com/highlight/detail?id=2678450628","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678450628?lang=zh_cn&edition=full","pubTime":"2026-10-28 17:53","pubTimestamp":1793181234,"startTime":"0","endTime":"0","summary":"金吾财讯 | 葛兰素史克 披露2026年第三季度财报，期内公司非GAAP每股收益0.55英镑，较预期高0.04英镑；总营收88.9亿英镑，同比增长4%，较预期高出5000万英镑。其中肿瘤板块收入6亿英镑，增幅23%；呼吸免疫炎症、HIV药物分别录得21%、10%的增长。现金流表现稳健，三季度经营现金流31亿英镑，自由现金流21亿英镑。分红方面，三季度派发每股17便士股息，全年目标股息为每股70便士。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/MjdiYzQwMTAxNzg2ODk4MjI3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MjdiYzQwMTAxNzg2ODk4MjI3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"307694","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GBPmain","GSK","BK4585","GSK.UK","FXB","GSKH","VIG","BK4007","MGBPmain","LU1829250122.USD","BK4588","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678459316","title":"葛兰素史克第三季度销售额增长，专科药物业务表现强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2678459316","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678459316?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:15","pubTimestamp":1793175300,"startTime":"0","endTime":"0","summary":"葛兰素史克第三季度营业额达118.3亿美元，同比增长4%。根据公司提供的分析师一致预期，市场此前预计葛兰素史克第三季度营业额为88.4亿英镑。专科药物销售额大幅增长，帮助葛兰素史克抵消了疫苗业务收入下降以及普通药物业务表现持平的影响。第三季度税前利润为19.4亿英镑，低于上年同期的24.6亿英镑。剔除特殊项目及汇率变动影响后，葛兰素史克第三季度核心营业利润同比增长5%，至30.8亿英镑。葛兰素史克重申了全年业绩指引。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-10-28/doc-iniwukpu6601410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","GSKH","LU1829250122.USD","BK4007","BK4532","GSK.UK","GSK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105620223","title":"异动解读｜葛兰素史克盘前下跌4.63%，Q3业绩虽超预期但每股收益同比微降","url":"https://stock-news.laohu8.com/highlight/detail?id=1105620223","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105620223?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:03","pubTimestamp":1793174591,"startTime":"0","endTime":"0","summary":"10月28日，葛兰素史克盘前下跌4.63%，报48.52美元/股，成交额92.9万美元。消息面上，公司公布第三季度调整后每股收益1.47美元，高于市场预期的1.40美元；销售额119.48亿美元，也高于预期的118.00亿美元。不过，调整后每股收益较上年同期的1.48美元微降0.68%，市场反应偏谨慎。近期公司基本面消息较多，包括乙肝药物Hibsago获批、Jemperli在直肠癌适应症取得进展，以及肿瘤管线扩张计划推进，但本次股价异动的直接催化仍是最新财报发布后的交易反应。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"葛兰素史克盘前走低，财报微降引发谨慎","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677948777","title":"GSK新药引爆乙肝功能性治愈赛道 多家本土药企角逐千亿市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2677948777","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677948777?lang=zh_cn&edition=full","pubTime":"2026-10-23 14:14","pubTimestamp":1792736040,"startTime":"0","endTime":"0","summary":"作为全球乙肝第一大国，中国不仅承载了全球近三分之一的患者群体，也正在成为乙肝功能性治愈研发最活跃的市场。这场由GSK引爆的赛道竞赛中，本土企业谁在领跑？目前，国内乙肝功能性治愈研发已形成了四条并行的技术路线，对应不同的作用机制。而歌礼制药、腾盛博药在乙肝治愈赛道则处于劣势地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-10-23/doc-iniweuqu2003347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1829250122.USD","BK4532","GSKH","GSK","BK4561","BK4200","BK4007","BK4588","BK4585","ASO","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2677986175","title":"牛市早报｜中办、国办：以原创性颠覆性科技创新培育壮大新兴产业和未来产业","url":"https://stock-news.laohu8.com/highlight/detail?id=2677986175","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677986175?lang=zh_cn&edition=full","pubTime":"2026-10-22 08:12","pubTimestamp":1792627956,"startTime":"0","endTime":"0","summary":"【市场数据】截至10月21日收盘，上证综指跌0.6%，报3713.03点；深证成指跌0.82%，报11704.35点；创业板指跌1.62%，报2694.71点。纽约股市三大股指21日上涨。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610223903322252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610223903322252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1829250122.USD","GSK","ASO","GSKH","BK4200","GSK.UK","BK4532","BK4585","BK4007","BK4561","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131694044","title":"异动解读｜葛兰素史克夜盘下跌3.61%，Jemperli获FDA加速批准后市场反应分化","url":"https://stock-news.laohu8.com/highlight/detail?id=1131694044","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131694044?lang=zh_cn&edition=full","pubTime":"2026-10-21 15:00","pubTimestamp":1792566054,"startTime":"0","endTime":"0","summary":"10月21日，葛兰素史克夜盘下跌3.61%，报48.8美元，成交额9.78万美元。最新消息面上，公司免疫疗法Jemperli获美国FDA加速批准，用于部分局部晚期直肠癌患者，覆盖错配修复缺陷或微卫星高度不稳定肿瘤人群。此次批准基于Ⅱ期研究中期结果：治疗后所有受试者均未检出癌症迹象，且93%的患者至少12个月维持无癌状态。该进展强化了公司肿瘤管线价值，但当前股价表现显示市场反应偏谨慎。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"葛兰素史克夜盘下跌，Jemperli获批后市场谨慎","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153951299","title":"财报前瞻 | 葛兰素史克营收预计增5.09%，机构指引或收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1153951299","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153951299?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:29","pubTimestamp":1792542595,"startTime":"0","endTime":"0","summary":"葛兰素史克将于2026年10月28日美股盘前发布财报，市场预期营收与每股收益温和增长，管线进展与成本优化成为关注焦点。市场一致预期本季度营收为116.05亿美元，同比增长5.09%；调整后每股收益为1.33美元，同比增长5.35%；EBIT为39.02亿美元，同比增长8.72%。上季度财报未披露本季度对营收、毛利率或净利率的明确指引，市场目前更侧重一致预期追踪。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | 葛兰素史克营收预计增5.09%，机构指引或收窄","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104020394","title":"异动解读｜葛兰素史克盘中上涨3.21%，Jemperli获FDA加速批准用于部分晚期直肠癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1104020394","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104020394?lang=zh_cn&edition=full","pubTime":"2026-10-21 03:46","pubTimestamp":1792525605,"startTime":"0","endTime":"0","summary":"10月21日，葛兰素史克盘中上涨3.21%，报51.05美元，成交额1.89亿美元。催化因素来自公司最新监管进展：Jemperli获美国FDA加速批准，用于治疗部分局部晚期直肠癌患者。此次获批覆盖错配修复缺陷或微卫星高度不稳定肿瘤患者。依据Ⅱ期研究中期结果，治疗后所有受试者均未检出癌症迹象，且93%的患者至少12个月维持无癌状态。该进展有望帮助部分患者避免化疗、放疗及手术，强化公司肿瘤管线价值。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"葛兰素史克上涨，Jemperli获FDA加速批准","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101882516","title":"异动解读｜葛兰素史克盘中上涨3.03%，比利时疫苗业务重组计划受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1101882516","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101882516?lang=zh_cn&edition=full","pubTime":"2026-10-14 23:24","pubTimestamp":1791991499,"startTime":"0","endTime":"0","summary":"10月14日，葛兰素史克盘中上涨3.03%，报47.67美元/股，成交额8913.55万美元。消息面上，公司被报道拟重组比利时疫苗业务，并在当地最多裁减1217个岗位。此次调整涉及瓦夫尔、里克斯萨特和根布卢三个基地，主要影响研发、行政及全球支持部门，一线生产人员 reportedly 不受影响，后续还将与工会展开协商。此外，市场近期也在关注公司新一轮成本节约计划。机构最新预期其第三季度业绩整体大致符合预期，年内焦点正转向成本优化与后续关键临床启动。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葛兰素史克盘中上涨，疫苗重组与成本优化引关注","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675310120","title":"据报葛兰素史克（GSK）正重组疫苗业务 拟在比利时裁员至多1217人","url":"https://stock-news.laohu8.com/highlight/detail?id=2675310120","media":"金吾财讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675310120?lang=zh_cn&edition=full","pubTime":"2026-10-14 17:43","pubTimestamp":1791971037,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据多家外媒周三报道，英国制药巨头葛兰素史克（GSK）已向企业委员会正式宣布重组计划，拟在其位于比利时的三个疫苗业务基地（瓦夫尔、里克斯萨特和根布卢）裁减至多1217个职位。报道称，本次裁员主要集中于旗下负责疫苗研发与生产的葛兰素史克生物制品公司（GSK Biologicals），受影响群体涵盖研发、行政及全球支持部门的员工与管理人员，而一线生产人员则不受影响。根据比利时劳工法律（即“雷诺程序”），GSK在实施集体裁员前必须与工会展开四阶段的结构化协商。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"307174","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","GSK.UK","BK4588","GSKH","GSK","BK4007","159646","LU1829250122.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165449525","title":"异动解读｜葛兰素史克盘中下跌3.04%，报49.515美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165449525","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165449525?lang=zh_cn&edition=full","pubTime":"2026-09-18 23:09","pubTimestamp":1789744170,"startTime":"0","endTime":"0","summary":"9月18日，葛兰素史克盘中下跌3.04%，报49.515美元/股，成交额4074.3万美元。葛兰素史克所在的制药行业中，个股中，礼来跌0.81%，强生跌0.77%，IM Cannabis Corp涨253.45%，默沙东跌0.71%，辉瑞跌0.92%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668694451","title":"全球药企“抢滩”中国管线：从成本嫁接走向早期合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2668694451","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668694451?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:14","pubTimestamp":1789722892,"startTime":"0","endTime":"0","summary":"从“产品出海”到“生态融合”，中国生物医药的全球化合作出现新的变化。国家药监局数据显示，2026年1—6月，中国创新药对外授权交易共81笔，总额约1100亿美元，已达2025年全年总额的八成，创历史新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609183878667977.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609183878667977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1829250122.USD","GSKH","GSK.UK","BK4007","BK4532","BK4585","GSK","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637649","title":"葛兰素史克（GSK）拟斥资7.5亿美元收购Chimagen旗下TCE项目全球独家权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667637649?lang=zh_cn&edition=full","pubTime":"2026-09-15 18:32","pubTimestamp":1789468371,"startTime":"0","endTime":"0","summary":"金吾财讯 | 葛兰素史克（GSK）已与Chimagen Biosciences达成协议，将以高达7.5亿美元的交易总额，收购后者一款用于治疗多发性骨髓瘤的三特异性T细胞衔接器（TCE）项目的全球独家权益。根据协议，GSK将向Chimagen支付一笔首付款，并根据后续研发与商业化进展支付相应的里程碑付款。该候选药物能够同时靶向T细胞及两种肿瘤相关抗原，目前预计将于2027年正式进入I期临床试验阶段。此前，双方已就另一款处于I期临床、针对CD19/CD20的双重TCE药物CMG1A46达成合作，本次交易标志着GSK在多发性骨髓瘤及血液瘤产品线上的进一步深化布局。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306052","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","LU1829250122.USD","BK4585","GSKH","GSK.UK","BK4007","BK4588","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111956752","title":"异动解读｜葛兰素史克盘中上涨4.07%，肺癌药Jideytro一线试验达94%缓解率","url":"https://stock-news.laohu8.com/highlight/detail?id=1111956752","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111956752?lang=zh_cn&edition=full","pubTime":"2026-09-14 21:38","pubTimestamp":1789393100,"startTime":"0","endTime":"0","summary":"9月14日，葛兰素史克盘中上涨4.07%，报50.0美元/股，成交额2419.23万美元。消息面上，公司公布旗下肺癌药物zidesamtinib一线治疗临床试验数据，在未经靶向治疗的晚期ROS1阳性肺癌患者中实现94%的客观缓解率；脑转移患者应答率达100%，其中70%实现完全肿瘤清除。公司计划年内向FDA提交一线适应症扩展申请。此外，GSK授权方翰森制药报告其ADC药物Ris-Rez治疗复发性小细胞肺癌的III期试验达到主要终点，进一步提振市场对GSK肿瘤管线的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葛兰素史克盘中上涨，肺癌新药缓解率达94%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120774041","title":"异动解读｜葛兰素史克盘前上涨3.32%，肺癌药Jideytro一线试验达94%缓解率远超同类","url":"https://stock-news.laohu8.com/highlight/detail?id=1120774041","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120774041?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:02","pubTimestamp":1789380156,"startTime":"0","endTime":"0","summary":"9月14日，葛兰素史克盘前上涨3.32%，报49.73美元/股，成交额84.86万美元。公司计划年内向FDA提交一线适应症扩展申请。Jideytro是GSK首个商业化肺癌药物，此前已获FDA批准用于经治ROS1阳性肺癌，一线数据的强劲表现为其\"重磅炸弹级\"销售潜力提供了有力支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葛兰素史克盘前上涨，肺癌新药缓解率达94%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":-0.044},{"period":"1month","weight":0.0355},{"period":"3month","weight":-0.0536},{"period":"6month","weight":-0.0356},{"period":"1year","weight":0.0507},{"period":"ytd","weight":-0.0069}],"compareEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.0199},{"period":"3month","weight":-0.0201},{"period":"6month","weight":0.0311},{"period":"1year","weight":0.1039},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"GSK Plc于1999年12月6日在英国成立的公众服务有限公司，是一个世界领先的研究型制药和保健公司，由Glaxo Wellcome plc和SmithKline Beecham plc合并而成。公司致力于开发较现有治疗方案明显改善的新产品，为病人和政府、保险公司或其他第三方提供帮助。","yearOnYearQuotes":[{"month":1,"riseRate":0.586957,"avgChangeRate":0.013809},{"month":2,"riseRate":0.478261,"avgChangeRate":0.001243},{"month":3,"riseRate":0.608696,"avgChangeRate":0.019112},{"month":4,"riseRate":0.659574,"avgChangeRate":0.030828},{"month":5,"riseRate":0.404255,"avgChangeRate":-0.008644},{"month":6,"riseRate":0.595745,"avgChangeRate":0.010234},{"month":7,"riseRate":0.531915,"avgChangeRate":0.003565},{"month":8,"riseRate":0.574468,"avgChangeRate":0.00509},{"month":9,"riseRate":0.510638,"avgChangeRate":0.004965},{"month":10,"riseRate":0.531915,"avgChangeRate":0.013376},{"month":11,"riseRate":0.468085,"avgChangeRate":0.009358},{"month":12,"riseRate":0.608696,"avgChangeRate":0.014188}],"exchange":"NYSE","name":"葛兰素史克","nameEN":"GlaxoSmithKline PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葛兰素史克,GSK,葛兰素史克股票,葛兰素史克股票老虎,葛兰素史克股票老虎国际,葛兰素史克行情,葛兰素史克股票行情,葛兰素史克股价,葛兰素史克股市,葛兰素史克股票价格,葛兰素史克股票交易,葛兰素史克股票购买,葛兰素史克股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}